Chester County News and Community Website
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) unveiled new two-year data showing that its flagship therapy Rezdiffra produced sustained improvements in patients with compensated MASH cirrhosis, a population with …
Breakthrough Liver Drug Shows Powerful Two-Year Gains — But Raises a Critical Warning Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced that it will present multiple new analyses on its MASH therapy, Rezdiffra (resmetirom), at the upcoming American Association for the Study …
Madrigal to Unveil New Rezdiffra Data at Key Liver Disease Conference Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals (NASDAQ: MDGL) announced Monday it has secured exclusive global rights to develop and commercialize SYH2086, a preclinical oral GLP-1 receptor agonist, through a licensing deal with …
Madrigal Licenses Oral GLP-1 Drug From CSPC, Targets Next-Gen MASH Therapy Read More
WASHINGTON, D.C. — The U.S. Department of Health and Human Services (HHS) has issued a final rule designed to expand access to kidney and liver transplants for patients with HIV. By …
HHS Finalizes Rule to Expand Kidney and Liver Transplants for Individuals with HIV Read More
WASHINGTON, D.C. — On Monday, the Food and Drug Administration (FDA) approved Iqirvo (elafibranor) oral tablets to treat primary biliary cholangitis (PBC). This rare autoimmune disease causes inflammation and damage …
FDA Approves New Treatment for Rare Liver Disease Read More
PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM), a pioneering biotechnology firm, has unveiled promising preclinical data for an innovative treatment approach to liver fibrosis, a condition currently posing significant …
Carisma Therapeutics Showcases Breakthrough in Liver and Lung Fibrosis Treatment Read More